비교리스트

 카트 문의
시장보고서
상품코드
1514248

세계의 여성 건강 치료 시장

Women´s Health Therapeutics
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 92 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

여성 건강 치료 시장은 2030년까지 454억 달러에 달할 전망입니다.

2023년에 196억 달러로 평가된 여성 여성 건강 치료 시장은 분석 기간에 복합 연간 성장률(CAGR) 12.7%로 성장하고 2030년에는 454억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 폐경 후 골다공증 애플리케이션은 복합 연간 성장률(CAGR) 14.9%로 성장을 지속하고, 분석 기간이 끝날 때까지 181억 달러에 도달할 것으로 예측됩니다. 호르몬 불임 응용 분야의 성장률은 분석 기간 동안 복합 연간 성장률(CAGR) 10.3%로 추정됩니다.

미국 시장은 51억 달러로 평가된 반면 중국은 복합 연간 성장률(CAGR) 17.0%로 성장할 것으로 예측됩니다.

미국 여성 건강 치료 시장은 2023년 51억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 113억 달러 규모에 이를 것으로 예측되며 예측 기간 동안 복합 연간 성장률(CAGR) 17.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 복합 연간 성장률(CAGR) 각각 8.4%와 10.7%로 예측되고 있습니다. 유럽에서는 독일이 복합 연간 성장률(CAGR) 약 9.8%로 성장할 것으로 예측됩니다.

세계 여성 건강 치료 시장 - 주요 촉진요인과 동향 요약

여성 건강 치료는 여성에게 영향을 미치는 건강 문제를 해결하기 위해 특별히 설계된 광범위한 치료 및 솔루션을 포함합니다. 이 카테고리에는 유방암, 자궁경부암, 골다공증, 갱년기 장애, 생식기능 장애 등 여성 특유 또는 여성에서 흔히 발견되는 질환을 대상으로 한 약물 치료, 치료법, 예방 치료가 포함됩니다. 이러한 치료제는 다양한 라이프 스테이지에 있는 여성의 QOL(생활의 질)과 건강 상태를 개선하고, 신체와 생식 양면의 건강을 지원하는 것을 목적으로 합니다. 사춘기부터 폐경 후까지 다양한 라이프 스테이지 여성에 대응하는 건강 서비스에 대한 수요가 높아지는 가운데 여성 건강 치료 시장이 확대되고 있습니다.

여성 건강 치료 시장을 견인하는 것은 몇 가지 중요한 요인이며, 특히 여성의 건강 문제에 대한 인식과지지 증가입니다. 공중 위생 캠페인과 여성 옹호 단체는 유방암과 난소암 등의 질병에 대한 인식을 높이고 조기 진단과 조기 치료에 연결하는데 매우 중요한 역할을 담당하고 있습니다. 노인 여성은 심혈관 질환, 골다공증, 폐경 등의 만성 건강 문제를 경험할 가능성이 높기 때문입니다. 게다가 의약품과 생명공학의 발전으로 여성 특유의 질병에 대한 보다 효과적인 치료법이 개발되어 환자의 예후를 개선하고 수명을 연장할 수 있게 되었습니다. 이러한 진보에는 호르몬 보충 요법, 표적 암 치료, 불임 치료 개선 등이 포함되어 모두 최근 큰 혁신과 채용을 볼 수 있습니다.

여성 건강 치료 시장의 최근 동향은 맞춤형 의료 및 표적 치료로의 전환을 보여줍니다. 특히 유방암이나 난소암 등 바이오마커나 유전자검사에 의해 치료효과를 예측할 수 있는 분야에서는 개별 환자의 유전자 프로파일이나 분자 프로파일에 맞춘 치료법의 개발에 주목을 받고 있습니다. 또한 폐경기 증상을 관리하기 위한 비호르몬 요법의 연구개발에 대한 투자도 증가하고 있습니다. 이것은 심각한 부작용을 동반할 수 있는 전통적인 호르몬 보충 요법을 대체하는 치료법에 대한 수요를 뒷받침합니다. 또 다른 주목할만한 동향은 모바일 건강 앱과 웨어러블 디바이스를 포함한 디지털 건강 기술의 통합으로 중요한 건강 지표를 추적하고 개인화된 건강 인사이트을 제공하여 여성 건강 관리를 지원합니다. 하도록 설계되었습니다. 이러한 기술은 여성이 자신의 건강을 관리할 수 있도록 하는 데 중요한 역할을 하며 다양한 건강 상태의 예방, 조기 발견 및 관리를 위한 도구를 제공합니다.

조사 대상 기업 예(주목의 36사)

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CooperSurgical, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

BJH 24.07.25

Global Women's Health Therapeutics Market to Reach US$45.4 Billion by 2030

The global market for Women Women's Health Therapeutics estimated at US$19.6 Billion in the year 2023, is expected to reach US$45.4 Billion by 2030, growing at a CAGR of 12.7% over the analysis period 2023-2030. Postmenopausal Osteoporosis Application, one of the segments analyzed in the report, is expected to record a 14.9% CAGR and reach US$18.1 Billion by the end of the analysis period. Growth in the Hormonal Infertility Application segment is estimated at 10.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 17.0% CAGR

The Women's Health Therapeutics market in the U.S. is estimated at US$5.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 17.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 10.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.8% CAGR.

Global Women's Health Therapeutics Market - Key Drivers and Trends Summarized

Women's health therapeutics encompass a broad range of medical treatments and solutions specifically designed to address health issues that affect women. This category includes medications, therapies, and preventive treatments targeting conditions unique to or more prevalent in women, such as breast cancer, cervical cancer, osteoporosis, menopause, and reproductive health disorders. These therapeutics aim to improve the quality of life and health outcomes for women across various life stages, supporting both physical and reproductive health. With an increasing demand for health services that cater to women through various stages of life—from puberty to post-menopause—the landscape of women's health therapeutics is expanding.

The market for women's health therapeutics is driven by several key factors, notably the increasing awareness and advocacy around women's health issues. Public health campaigns and women's advocacy groups have been pivotal in increasing awareness about diseases such as breast and ovarian cancer, leading to earlier diagnosis and treatment. The aging female population globally is another significant driver, as older women are more likely to experience chronic health issues such as cardiovascular diseases, osteoporosis, and menopausal health concerns. Furthermore, advancements in pharmaceuticals and biotechnology have led to the development of more effective treatments for conditions specific to women, enhancing patient outcomes and extending life expectancies. These advancements include hormone replacement therapies, targeted cancer therapies, and improved fertility treatments, which have all seen significant innovation and adoption in recent years.

Recent trends in the women's health therapeutics market indicate a shift towards personalized medicine and targeted therapies. There is a growing focus on developing treatments tailored to the genetic and molecular profiles of individual patients, particularly in areas such as breast and ovarian cancer, where biomarkers and genetic tests can predict treatment responses. Additionally, there is an increasing investment in research and development of non-hormonal therapies for managing menopause symptoms, driven by the demand for alternatives to traditional hormone replacement therapies, which can have significant side effects. Another notable trend is the integration of digital health technologies, including mobile health apps and wearable devices, designed to support women's health management by tracking vital health metrics and providing personalized health insights. These technologies are playing a crucial role in empowering women to take charge of their health, offering tools for prevention, early detection, and management of various health conditions

Select Competitors (Total 36 Featured) -

  • AstraZeneca
  • Bayer AG
  • Bristol-Myers Squibb Company
  • CooperSurgical, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Women's Health Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Chronic Diseases in Women
    • Growing Awareness and Focus on Women's Health Issues
    • Advancements in Hormonal Therapies
    • Expansion of Personalized Medicine in Women's Health
    • Rising Demand for Non-Invasive Therapeutic Solutions
    • Adoption of Digital Health Technologies and Telemedicine
    • Increasing Investment in Women's Health Startups
    • Impact of Aging Population on Therapeutics Demand
    • Development of Novel Drug Delivery Systems
    • Expansion of Preventive Healthcare Services
    • Influence of Lifestyle Changes and Urbanization
    • Rising Demand for Fertility and Reproductive Health Solutions
    • Growing Importance of Mental Health and Wellness for Women
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Women's Health Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Postmenopausal Osteoporosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Postmenopausal Osteoporosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Postmenopausal Osteoporosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Hormonal Infertility by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Hormonal Infertility by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Hormonal Infertility by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Polycystic Ovary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Polycystic Ovary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Polycystic Ovary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Contraceptives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Contraceptives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Menopause by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Menopause by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Menopause by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Women's Health Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 35: China Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: China Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: China 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 38: Europe Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: Europe Historic Review for Women's Health Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Europe 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 41: Europe Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Europe Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Europe 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 44: France Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: France Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: France 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 47: Germany Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Germany Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Germany 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 50: Italy Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Italy Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Italy 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 53: UK Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: UK Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: UK 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 56: Spain Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Spain Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Spain 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 59: Russia Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Russia Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Russia 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of Europe Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Rest of Europe 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 65: Asia-Pacific Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 66: Asia-Pacific Historic Review for Women's Health Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Asia-Pacific 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Asia-Pacific 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 71: Australia Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Australia Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Australia 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: India Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: India 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 77: South Korea Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: South Korea Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: South Korea 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 80: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Asia-Pacific Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Rest of Asia-Pacific 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 83: Latin America Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 84: Latin America Historic Review for Women's Health Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Latin America 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Latin America Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Latin America 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 89: Argentina Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Argentina Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Argentina 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 92: Brazil Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Brazil Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Brazil 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 95: Mexico Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Mexico Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Mexico 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 98: Rest of Latin America Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Latin America Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Latin America 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 101: Middle East Recent Past, Current & Future Analysis for Women's Health Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 102: Middle East Historic Review for Women's Health Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Middle East 16-Year Perspective for Women's Health Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 104: Middle East Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Middle East Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Middle East 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 107: Iran Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Iran Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Iran 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 110: Israel Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Israel Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Israel 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 113: Saudi Arabia Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Saudi Arabia Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Saudi Arabia 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 116: UAE Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: UAE Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: UAE 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 119: Rest of Middle East Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Rest of Middle East Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Rest of Middle East 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Women's Health Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 122: Africa Recent Past, Current & Future Analysis for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Africa Historic Review for Women's Health Therapeutics by Application - Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Africa 16-Year Perspective for Women's Health Therapeutics by Application - Percentage Breakdown of Value Sales for Postmenopausal Osteoporosis, Hormonal Infertility, Polycystic Ovary Syndrome, Endometriosis, Contraceptives, Menopause and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제